Saturday, May 27, 2017
 
 
Company News: Page (1) of 1 - 05/19/17 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Concord Medical Announces the Acquisition of Shanghai ProMed Cancer Center, LLC
 
(May 19, 2017)

BEIJING, May 19, 2017 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced that its subsidiary, Meizhong Jiahe Hospital Management Corp. Ltd ("MHM"), previously known as CMS Hospital Management Co., Ltd, jointly with Guofu Huimei Investment Management Limited Partnership ("Guofu Huimei"), proposed to acquire Shanghai ProMed Cancer Center ("ProMed"), LLC by purchasing existing, and subscribing for newly increased, registered capital of ProMed. The acquisition is pending necessary shareholder approval and governmental filings. MHM will hold 31.64% of the equity interest in ProMed after the completion of the acquisition.

ProMed is equipped with advanced medical equipment such as linear accelerators, CTs, MRIs, Mo-target mammography, CDFI and telepathology consultation systems. It is located at the campus of Shanghai Ruijin Hospital, Luwan Branch which conveniently provides a wealth of medical resources for patients. As an outpatient cancer clinic, ProMed medical services including diagnostic imaging, radiation oncology, medical oncology such as chemotherapy, targeted therapy and immunization therapy to its patients. In addition, ProMed is developing strategic cooperation with internationally renowned cancer treatment institutions to advance its service procedure, clinical skills, quality management and talent training system, aiming to improve patient cure rate and life quality. ProMed will provide high-end clinical tumor diagnosis and treatment services to public medical insured patients and business insured patients as well.

Dr. Jianyu Yang, Chairman and CEO of Concord Medical, commented, "The acquisition of ProMed is a critical point for the Company's long-term strategy of developing a specialized cancer hospital chain in China. The unique regional advantage, independent medical institution license and high-end equipment ensures that ProMed will be the flagship cancer center under Meizhong Jiahe brand. Besides, we will upgrade the service procedure, clinical skills, quality management and talent training system by cooperating with internationally renowned cancer treatment institutions, for providing better cancer diagnosis and treatment.


About Concord Medical

Concord Medical Services Holdings Limited is a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China.  As of April 30, 2017, the Company operated a network of 95 centers with 57 hospital partners that spanned 49 cities and 19 provinces and administrative regions in China.  Under long-term arrangements with top-tier hospitals in China, the Company provides radiotherapy and diagnostic imaging equipment and manages the daily operations of these centers, which are located on the premises of its hospital partners.  The Company also provides ongoing training to doctors and other medical professionals in its network of centers to ensure a high level of clinical care for patients.  As part of its high-end cancer hospital development strategy and oversea business extension, the Company acquired Concord Cancer Hospital, a private hospital in Singapore in April, 2015.  For more information, please see http://ir.concordmedical.com.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward- looking statement. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For more information, please contact:

Concord Medical Services
Mr. Ting Jia (Chinese and English)
+86 10 5903 6688 (ext. 809)
ting.jia@concordmedical.com

Mr. Mike H. Cheng (Chinese and English)
+86 10 5903 6688 (ext. 609)
hao.cheng@concordmedical.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/concord-medical-announces-the-acquisition-of-shanghai-promed-cancer-center-llc-300460625.html

SOURCE Concord Medical

Copyright 2014 PR Newswire. All Rights Reserved


Page: 1


Related Keywords:USA, China, Cancer, Surgery, Womens Health, Business, Science, Healthcare, Hospitals, Medical, Cancer, Business, china, Other,
Related Sites: itbusinessnet.com ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   IBN - IT Weekly Newsletter ,   DMN Newswire Newsletter
 
 
 
 
 
Seniors

Drugs
  • Silver Birch of Hammond Affordable Assisted Lifestyle Community Opens Doors
  • NetDirector Enables Next-Generation Integration in Radiology with American Health Imaging
  • APR Applied Pharma Research at the 9th ChinaBio® Partnering Forum: Bringing Swiss Made Innovations and Science Driven Technologies to Strengthen Its Presence in the Chinese Market
  • Medical Imaging Equipment Market Is Expected To Reach USD 44,887.4 Mn By 2022, Credence Research
  • Growth Opportunities in the Global Diagnostic Imaging Market, 2017-2022 - Research and Markets

    Cancer
  • Artificial Intelligence Firm Set to Revolutionize Healthcare
  • Mesothelioma Compensation Center Now Urges the Family of a Person Who Recently Died From Mesothelioma Before They Could Hire a Lawyer to File a Claim to Call for Instant Help
  • Mapi Research Trust Unveils New Clinical Outcome Assessments (COA) Website for the Zarit Burden Interview (ZBI) Questionnaire
  • Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2010 - 2017: Deal trends, players, financials and forecasts
  • Peptide Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines